Skip to main content

TherapeuticsMD, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited - in thousands)

Common Stock · Additional Paid in · Accumulated
SharesAmountCapitalDeficitTotal
Balance, January 1, 202611,574$11$979,256$(952,391)$26,876
Share-based compensation——2—2
Net income———9595
Balance, March 31, 202611,574$11$979,258$(952,296)$26,973
Share-based compensation——4—4
Net income———155155
Balance, June 30, 202611,574$11$979,262$(952,141)$27,132
Common Stock · Additional Paid in · Accumulated
SharesAmountCapitalDeficitTotal
Balance, January 1, 202511,532$11$979,181$(951,822)$27,370
Share-based compensation42—23—23
Net loss———(653)(653)
Balance, March 31, 202511,574$11$979,204$(952,475)$26,740
Share-based compensation——1—1
Net income———551551
Balance, June 30, 202511,574$11$979,205$(951,924)$27,292
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.